ReviewCurrent cardiology reports2018
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Kazuomi KarioPubMed ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this paperpooled ittrialcites it